Summary & Overview
HCPCS A9590: Iodine I-131 Iobenguane, 1 millicurie
HCPCS Level II code A9590 denotes a 1 millicurie unit of iodine I-131 labeled iobenguane, a radiopharmaceutical used in nuclear medicine for targeted diagnostic imaging and select therapeutic applications. Nationally, accurate coding for radiopharmaceuticals like A9590 affects billing, inventory tracking, and clinical workflow for facilities that administer radioactive agents.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, reimbursement benchmarks where available, and clinical context for use of iobenguane I-131. Readers will find a concise overview of typical sites of service, relevant service line considerations, common billing modifiers (listed separately), and guidance on documentation elements that support medical necessity determinations.
Coverage and reimbursement practices for radiopharmaceuticals vary by payer and setting; this resource summarizes common contractual approaches and highlights areas where policy updates or local payer edits frequently occur. The piece also provides practical benchmarks for claim line reporting and notes when additional documentation or prior authorization is commonly required. Data not available in the input is identified where applicable.
Billing Code Overview
HCPCS Level II code A9590 represents Iodine I-131, iobenguane, 1 millicurie. This itemized code describes a radiopharmaceutical dosage unit used for diagnostic imaging or therapeutic procedures involving radioactive iodine-labeled iobenguane.
Service type: Radiopharmaceutical dose
Typical site of service: Nuclear medicine departments, hospital outpatient imaging centers, and specialized radiology or oncology clinics equipped to handle radiopharmaceutical administration and imaging.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to nuclear medicine for administration of A9590 (iodine I-131 iobenguane, 1 millicurie) as part of diagnostic scintigraphy or therapeutic planning for neuroendocrine tumors such as pheochromocytoma or neuroblastoma. The clinical workflow begins with an outpatient or inpatient consult by an endocrinologist, oncologist, or pediatric oncologist who orders the radiopharmaceutical study. Prior to administration, review of patient medication, pregnancy status, renal function, and recent imaging is performed. The patient receives pre-procedure counseling regarding radiation safety and potential side effects. On the day of service, a nuclear medicine technologist or authorized radiopharmacist prepares and performs dose verification in a licensed radiopharmacy area, documents lot and activity, and administers the radiopharmaceutical via intravenous injection under nuclear medicine supervision. Post-administration imaging is obtained per protocol (planar and/or SPECT/CT) at institution-specific time points. Radiation safety protocols for patient release, waste handling, and caregiver instructions are provided. Clinical interpretation and final report are completed by a board-certified nuclear medicine physician or radiologist with nuclear medicine training, who also communicates results to the referring clinician for staging, localization, or therapeutic planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |